The clinical data of KEYNOTE-028 ovarian cancer indicated that the overall response rate (ORR) of the 26 PD-L1-positive epithelial ovarian cancer patients who received pembrolizumab treatment was 11.5%, while their median progression-free survival and OS values were recorded to be 1.9 months and 13.1 months, respectively [32]. This evidence concerns the gene CD274 and ovarian carcinoma.